Surrozen pauses SZN-1326 Phase 1 trial due to liver enzyme elevations; Q3 net loss $13.4M

Surrozen, Inc./DE

Voluntarily paused SZN-1326 Phase 1 SAD trial after grade 3 ALT/AST elevations in 3 subjects; transaminases resolved spontaneously.
SZN-043 Phase 1 ongoing but with grade 1-2 transaminase elevations; re-evaluating timeline.
Entered partnership with Boehringer Ingelheim for SZN-413; upfront $12.5M, milestones up to $586.5M plus royalties.
Q3 2022 cash $78.4M (down from $92.7M in Q2); R&D expense $8.6M, net loss $13.4M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Surrozen, Inc./DE reported the quarter ended September 30, 2022 results: net income $13.4 million.

Period: the quarter ended September 30, 2022
Net income: $13.4 million
Result: reported results

Exact text from the filing

Net loss for the third quarter ended September 30, 2022 was $13.4 million, as compared to $14.0 million for the same period in 2021.

View on SEC.gov

Browse all earnings releases →

Surrozen, Inc./DE filing history →

Source: SEC EDGAR

accession 0000950170-22-025228

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.